Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL had received approval in Canada to manufacture and market Tamsulosin Hydrochloride Capsules 0.4 mg from Health Canada, Therapeutic Products Directorate (TPD). This product has proven to be bio- equivalent to Flomax(R) Capsules which is indicated for the treatment of Benign Prostatic Hyperplasia (BPH). The total market for both generic and brand Tamsulosin Hydrochloride Capsules in Canada is CAD $22 million (IMS-MAT: March 2007).
"We are pleased to receive this approval from TPD
for Tamsulosin Hydrochloride Capsules that will expand Ranbaxy's
expanding product portfolio of accessible and affordable generic
product offerings. We are also quite proud of the fact that this
formulation was fully developed within our parent company Ranbaxy
Laboratories Limited, which further demonstrates the capabilities and
competencies of the Ranbaxy organization. This is the fourth
product to be added to our product portfolio through this pathway in
2007. RPCI's Sales Team will be offering Ran(R)-Tamsulosin
immediately under the Ranbaxy label in all of the Canadian provinces
that now provides another
option to pharmacist for this molecule, that will be of benefit to both
patients and the Canadian Health Care system," said Paul Drake,
President, RPCI.
Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in
Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy
Laboratories Limited (RLL), India's largest pharmaceutical
company. RPCI is engaged in the sale and distribution of generic
prescription products in the Canadian healthcare system.
Ranbaxy Laboratories Limited, headquartered in
India, is an integrated, research based, international pharmaceutical
company producing a wide range of quality, affordable generic
medicines, trusted by healthcare professionals and patients across
geographies.
Ranbaxy's continued focus on R&D has resulted in
several approvals in developed markets and significant progress in New
Drug Discovery Research. The Company's foray into Novel Drug Delivery
Systems has led to proprietary "platform technologies", resulting in a
number of products under development.
The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11countries.
Canadian Pharmacy - online pharmaceutical store!
Hoodia gordonii
Online Pharmacy No prescription pharmacy